Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNA2 | P51530 | 1/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 4/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277854 | 0.85 | DNA2 (0.83) | DNA2CASP6CTDSP1CLK1DYRK1A | |
| SCHEMBL3066032 | 0.82 | DNA2 (0.66) | DNA2CASP6CTDSP1CLK1DYRK1A | |
| SCHEMBL6215533 | 0.79 | DNA2 (0.61) | DNA2CASP6CTDSP1CLK1DYRK1A | |
| SCHEMBL23538255 | 0.77 | CLK1 (0.46) | DNA2CASP6CTDSP1CLK1TDP1 | |
| SCHEMBL4334739 | 0.77 | DNA2 (1.00) | DNA2CASP6CTDSP1CLK1DYRK1A | |
| SCHEMBL23198582 | 0.76 | DNA2 (0.52) | DNA2CASP6CTDSP1MAPTALDH1A1 | |
| SCHEMBL6537720 | 0.76 | DNA2 (0.78) | DNA2CASP6CTDSP1CLK1DYRK1A | |
| SCHEMBL14631629 | 0.76 | DYRK1A (0.45) | CLK1DYRK1AGSK3BCDK5CDK5R1 | |
| SCHEMBL5897373 | 0.76 | CLEC4M (0.57) | DNA2CASP6CTDSP1MAPTMAPK1 | |
| SCHEMBL1017079 | 0.75 | DNA2 (0.56) | DNA2CASP6CTDSP1CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601174-B1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2601174-B1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2601174-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2012019003-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012019003-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | IDO1, IDO2, INMT | DNA2 1188/4885CASP6 2572/4885CTDSP1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.